黄体激素拮抗剂 CETRORELIX 治疗 BPH 的 I/II 期试验-猫眼课题宝

黄体激素拮抗剂 CETRORELIX 治疗 BPH 的 I/II 期试验

批准号：

5224982

负责人：

ANA M COMARU-SCHALLY

金额：

$0.0万

依托单位：

依托单位国家：

美国

项目类别：

财政年份：

资助国家：

美国

项目状态：

未结题

起止时间：

至

来源：

https://reporter.nih.gov/project-details/5224982

关键词：

benign prostate hyperplasia clinical research clinical trial phase I human subject human therapy evaluation inhibitor /antagonist luteinizing hormone male urinary tract disorder chemotherapy

项目摘要

项目成果

ANA M COMARU-SCHALLY的其他基金

相似基金

相关文献

中文摘要

翻译

点击翻译按钮获取中文摘要

英文摘要

Open label phase I/II safety and efficacy study of LH-RH antagonist Cetrorelix, in 10 selected patients with benign prostatic hyperplasia who were unsuitable for prostatectomy or who refused transurethral resection. The study will be conducted in order to investigate the safety and efficacy of Cetrorelix (SB-75) therapy in 10 selected patients. Treatment with the LH-RH antagonist Cetrorelix will last for two months, after which the antagonist will be discontinued. After discontinuation of Cetrorelix therapy, patients will be followed on a monthly basis for three months or until the symptoms increase to a level which is greater than 50% of the maximum symptom reduction during the treatment period.

期刊论文(0)

专著(0)

科研奖励(0)

会议论文